May 25, 2020

C4U and Noile-Immune Biotech Partnership on PRIME Allogeneic
CAR-T Cell Therapy Using CRISPR/Cas3 Genome Editing Technology
Noile-Immune Biotech Inc., (“Noile-Immune”) and C4U Corporation,(“C4U”) today announced that they have entered into an agreement on joint
research and commercialization of next-generation allogeneic genemodified immune cell therapy combining C4U’s CRISPR/Cas3 genome
editing technology and Noile-Immune’s PRIME (Proliferation inducing andmigration enhancing) technology designed to improve proliferation andtrafficking of immune cells into solid tumors.
The CRＩSPR/Cas3 technology is the C4U’s core technology, which isdeveloped by the founders and advisors of Scientific Advisory Board ofC4U, Dr. Tomoji Mashimo, professor of the Institute of Medical Science,
the University of Tokyo, and Dr. Junji Takeda, guest professor of theResearch Institute for Microbial Diseases, Osaka University.
CRISPR/Cas3 is the technology that can counter the CRISPR/Cas9system, which is currently being researched all over the world, and isattracted attention as a promising genome editing technology that is notaffected by the complicated patent status related to Cas9.

The PRIME technology, the core technology of Noile-Immune, is related togene-modified immune cell therapies including CAR-T and TCR-T cells
against cancer, and was developed by Dr. Koji Tamada, the scientificfounder and director of Noile-Immune, professor of Yamaguchi University
Graduate School of Medicine and Invited Professor at Center for Gene andCell Therapy, The Institute of Medical Science, The University of Tokyo.
PRIME technology not only enhances the functions of gene-modified
immune cells by producing cytokines and chemokines, but also improves
the ability of patient's own immune systems to cope with cancer cells.

“I am very pleased to establish an alliance with C4U, which has a uniquegenome editing technology, “ said Dr. Tamada. “In this project, we will

develop highly active allogeneic CAR-T cell therapy by combining ourPRIME CAR-T technology and genome editing technology owned by C4U.
Combination of these Japan-origin technologies is expected to create nextgeneration CAR-T cells that are highly versatile and beneficial for manysolid cancer patients. This project aims to develop a stage-of-the-art cancer
immunotherapy under various research supports including MEXT’sProgram for Building Regional Innovation Ecosystems.”“Noile-Immune’s PRIME CAR-T technology is world’s innovativetechnology that overcoming the weak points of CAR-T cells on the solidcancer and the sustainability,” said Dr. Mashimo. “By combining ourCRISPR/Cas3 genome editing technology to PRIME CAR-T technology, it
is possible to produce more effective and superior allogeneic CAR-T celltherapy at reasonable cost compared to the conventional CAR-T celltherapy. We are confident that we can provide novel our therapy to anumber of patients who are fighting to cancer.”

Under this agreement, Noile-Immune and C4U will conduct joint researchon allogeneic gene-modified immune cell therapy. Noile-Immune will bearpart of the costs necessary to carry out this joint research. In addition, bothcompanies have the right to commercialize the results obtained by this joint
research, and the right to mutually receive royalties under the contract.
Noile-Immune will pay the access fee for the core technology of C4U whencommercializing. Additional terms of the agreement were not disclosed.

About Noile-Immune Biotech, Inc.
Noile-Immune is a biotechnology company focused on the development
and commercialization of novel cancer immunotherapy products withbreakthrough technology to eradicate cancer cells. The company aims todiscover and develop innovative cancer immunotherapies through thepartnerships with experts in academia including Yamaguchi University andThe National Cancer Center Japan, and deliver the first-in-class and best-in-class therapies to patients as well. Learn more at https://www.noileimmune.com/english.
About C4U Corporation
C4U（CRISPR for You） is a life science startup founded in March 2018 andoriginated from Osaka University. The company is working on thedevelopment of own core technology for new genome editing.
Learn more at http://www.crispr4u.jp/en/.